JSPR Insider Trading

Insider Ownership Percentage: 2.70%
Insider Buying (Last 12 Months): $4,532,500.00
Insider Selling (Last 12 Months): $84,546.00

Jasper Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Jasper Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Jasper Therapeutics Share Price & Price History

Current Price: $5.51
Price Change: Price Increase of +0.17 (3.18%)
As of 01/17/2025 05:00 PM ET

This chart shows the closing price history over time for JSPR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$5.51Closing price on 01/20/25:

SEC Filings (Institutional Ownership Changes) for Jasper Therapeutics (NASDAQ:JSPR)

79.85% of Jasper Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at JSPR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$5.04Mbought$1.38MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$100M$0$100MTotal InflowsTotal Outflows
Jasper Therapeutics logo
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Read More on Jasper Therapeutics

Today's Range

Now: $5.51
Low: $5.25
High: $5.89

50 Day Range

MA: $18.98
Low: $5.34
High: $23.97

52 Week Range

Now: $5.51
Low: $5.25
High: $31.01

Volume

720,615 shs

Average Volume

849,635 shs

Market Capitalization

$82.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18

Who are the company insiders with the largest holdings of Jasper Therapeutics?

Jasper Therapeutics' top insider investors include:
  1. Velan Capital Investment Manag (Major Shareholder)
  2. Carlyle Group Inc (Major Shareholder)
  3. Holding Ltd Roche (Major Shareholder)
  4. Jeetinder Singh Mahal (Insider)
  5. Jeetinder Singh Mahal (COO)
  6. William Lis (Director)
  7. Thomas G Wiggans (Director)
  8. Anna Louise French (Director)
Learn More about top insider investors at Jasper Therapeutics.